Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 11,257 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neonate Clear all

Conditions: Atopic Dermatitis
Interventions: 0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Melville, New York

Conditions: Pruritus, Atopic Dermatitis
Interventions: SRD174 Cream, vehicle cream; Drug · Other
Lead sponsor: Serentis Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 13
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Oceanside, California + 10 more

Conditions: Duchenne Muscular Dystrophy
Interventions: Deramiocel (CAP-1002); Biological
Lead sponsor: Capricor Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: Sacramento, California • Aurora, Colorado • St Louis, Missouri + 2 more

Conditions: Cystic Fibrosis
Interventions: CFTR Modulators; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Fragile X Syndrome
Interventions: AZD7325 (High-Dose), AZD7325 (Low-Dose), Placebo oral capsule; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cystic Fibrosis
Interventions: VX-828; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: O6-benzylguanine, temozolomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, sargramostim, busulfan, etoposide, fludarabine phosphate, prednisone, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Preterm Delivery
Interventions: Not listed
Lead sponsor: Obstetrix Medical Group; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 995 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 10
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 7 more

Conditions: Preterm Labor, Preterm Birth
Interventions: Multimodal intervention strategy; Other
Lead sponsor: Sera Prognostics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 6,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 18
States / cities: San Diego, California • New Haven, Connecticut • Newark, Delaware + 15 more

Conditions: Sickle Cell Disease, Thalassemia Major
Interventions: CliniMACS; Device
Lead sponsor: Timothy Olson; Other
Eligibility: 2 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: cyclophosphamide, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pulmonary Artery Stenosis, Tetralogy of Fallot, Pulmonary Atresia
Interventions: Pulmonary artery rehabilitation; Procedure
Lead sponsor: Aymen N Naguib; Other
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cystic Fibrosis
Interventions: VX-561, IVA, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 30
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 25 more

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more

Conditions: Cystic Fibrosis
Interventions: SPL84, Placebo; Drug · Other
Lead sponsor: SpliSense Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • Denver, Colorado • Boston, Massachusetts

Conditions: Hypertension, Neonatal
Interventions: Boppli; Device
Lead sponsor: Indiana University; Other
Eligibility: 0 Months to 9 Months
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Heart Failure Congenital, Single-ventricle
Interventions: Cardiac rehabilitation, Usual care; Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Stanford, California • Nashville, Tennessee

Conditions: Hypospadias
Interventions: Caudal block anesthesia, Dorsal penile nerve block anesthesia; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 4 Months to 4 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Retinitis Pigmentosa
Interventions: Argus II; Device
Lead sponsor: University of California, Santa Barbara; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Santa Barbara, California • Baltimore, Maryland • Ann Arbor, Michigan

Conditions: Primary Antibody Deficiency Disorders
Interventions: App-based exercise intervention; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Milford, Connecticut • North Haven, Connecticut

Conditions: Congenital Diaphragmatic Hernia
Interventions: Fetoscopic Endoluminal Tracheal Occlusion (FETO) Procedure; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions: BCG TICE Vaccine; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Congenital Hyperinsulinism
Interventions: RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3, RZ358 Sequential Group Cohort 4; Drug
Lead sponsor: Rezolute; Other
Eligibility: 2 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Fort Worth, Texas

Search by objective public record fields.

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

Phase IIa Safety and Efficacy Study of SRD174 Cream in Patients With AD-associated Pruritus

Open-label Extension of the HOPE-2 Trial

Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials

An Initial Study of AZD7325 in Adults With Fragile X Syndrome

A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Neonatal Outcome by Reason for Delivery

Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs

Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies

Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Retrospective Review of Anesthetic Considerations for Pulmonary Artery Rehabilitation

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis

Measurement of High Blood Pressure Using Boppli

REHAB Fontan Failure: A Trial of Cardiac Rehabilitation

Effect of Caudal and Penile Block on Hypospadias Repair Complications

The Perceptual Experience of Argus II Users

Exercise Intervention and Immunodeficiency

Safety and Efficacy of Fetoscopic Endoluminal Tracheal Occlusion in Congenital Diaphragmatic Hernia

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism